AURORA, ON, June 5 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that it has entered into an agreement with U.S.-based Noonan Russo, a division of Euro RSCG Life PR, in order to increase the public profile of Helix among the scientific research, pharmaceutical and investment communities in the United States, as well as to provide Helix's existing U.S. shareholders with timely information related to Helix. This initiative is being undertaken as the Company continues to engage U.S.-based scientific, technical and research services for its lead product development programs, and begins to explore the possibility of pursuing additional strategic partnerships to support its growing product development objectives. This initiative is also intended to introduce Helix to the U.S. capital markets, with a view to obtaining institutional support for possible future financings in the U.S. This agreement with Noonan Russo will complement Helix's Canadian communications strategy currently managed by The Equicom Group Inc. About Noonan Russo Noonan Russo, a division of Euro RSCG Life PR, is a leading healthcare public and investor relations consultancy delivering strategic programs that help transform companies into key leaders in their sectors. The agency's clients span the range of large pharmaceutical companies, to midsize and start-up biotech, medical device and healthcare companies. Noonan Russo has headquarters in New York City and offices in San Diego, California, Washington, DC, London, UK, and Paris, France. About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP", and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol. The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements regarding the Company's public profile, product development activities and finances, which statements can be identified by the use of forward-looking terminology such as "to increase", "possibility", "objectives", "intended", "future", "with a view to", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward-looking statements are statements about the future and are inherently uncertain, and Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, Helix's expectation of Noonan Russo's performance; research and development risks, including the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; uncertainty as to whether the Company's products will be successfully commercialized, or at all; Helix's need for additional future capital, which may not be available in a timely manner or at all; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, opinions or expectations, or other circumstances change. This release does not constitute an offer or sale of securities.